ReferencedFeature essay
TGN1412 Did Not Fail Because the Biology Was Empty. It Failed Because the Boundary Was Not Human-Safe Yet.
A strict pre-trial reading of why TGN1412 already looked fragile before first-in-human dosing.
Newsletter Archive
Evidence-locked essays on where oncology confidence broke
These editions are written under the same rule as the archive: pre-trial date lock, evidence lock, public-evidence bounds, and no hindsight at all.
Editorial Standard
No retrospective certainty
These essays are designed to show what looked strong, where the break point sat, and what the field could honestly have seen before the outcome became public.
ReferencedFeature essay
Neoantigen-specific TILs Looked Promising. The Fragility Was Already There.
A pre-trial reading of why neoantigen-specific TIL therapy in GI cancers looked biologically real but still too fragile for broad escalation.
ReferencedFeature essay
In Vivo CAR T Looked Promising. The Fragility Was Already There.
A pre-trial reading of why public evidence already pointed to escalation fragility in the ESO-T01 in vivo CAR T strategy.
ReferencedFeature essay
When Deeper Response Looked Like Stronger Control in Myeloma — But the Sequence Had Not Yet Proven It Could Hold
A decision-boundary reading of sequencing daratumumab and transplant in newly diagnosed multiple myeloma across LMIC settings.
ReferencedFeature essay
HER2 CAR-T in Solid Tumors Did Not Lack Signal. It Lacked a Stable Control Boundary.
A pre-trial reading of why early HER2 CAR-T signal in solid tumors did not justify broad escalation confidence.
ReferencedFeature essay
KRAS G12C Did Not Fail. It Was Never a Stable Control Point.
A pre-trial reading of early sotorasib logic and the difference between target validity and durable control.
ReferencedFeature essay
How TIGIT Combinations Looked Stronger Than Their Escalation Boundary.
A focused note on class contradiction, signal maturity, and why early support did not equal broad design confidence.